Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk Level in Multiple Myeloma

Comparing prognoses for high risk vs standard risk

Publish date:: August 12, 2015

Cytogenetically identified high-risk myeloma patients have worse prognoses than standard-risk myeloma patients after autologous hematopoietic stem cell transplantation (auto-HCT), according to a study of 670 patients with multiple myeloma (MM), including 74 with high-risk MM. Researchers found:

• Compared to standard-risk patients, high-risk patients had:

◊ Significantly lower overall response rates, 74% vs 85%.

◊ Shorter median progression-free survival (PFS), 10.3 months vs 32.4 months.

◊ Shorter overall survival (OS), 28 months vs not reached.

• Having only one high-risk cytogenetic abnormality or achieving at least very good partial remission after auto-HCT independently predicted improved PFS and OS in high-risk patients.

Citation: Kazmi SM, Nusrat M, Gunaydin H, et al. Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem cell transplantation [Published online ahead of print August 4, 2015]. Clin Lymph Myeloma Leuk. doi: http://dx.doi.org/10.1016/j.clml.2015.07.641.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,